Cargando…
SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments
Since the SARS-CoV-2 outbreak, pharmaceutical companies and researchers worldwide have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The potential pathogen responsible for Coronavirus Disease 2019 (COVID-19), SARS-CoV-2, belongs to a novel lineage of beta coronaviruses in...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780920/ https://www.ncbi.nlm.nih.gov/pubmed/36560555 http://dx.doi.org/10.3390/vaccines10122145 |
_version_ | 1784856946865602560 |
---|---|
author | Zhang, Xirui Yuan, Hao Yang, Zipeng Hu, Xiaoyu Mahmmod, Yasser S. Zhu, Xiaojing Zhao, Cuiping Zhai, Jingbo Zhang, Xiu-Xiang Luo, Shengjun Wang, Xiao-Hu Xue, Mengzhou Zheng, Chunfu Yuan, Zi-Guo |
author_facet | Zhang, Xirui Yuan, Hao Yang, Zipeng Hu, Xiaoyu Mahmmod, Yasser S. Zhu, Xiaojing Zhao, Cuiping Zhai, Jingbo Zhang, Xiu-Xiang Luo, Shengjun Wang, Xiao-Hu Xue, Mengzhou Zheng, Chunfu Yuan, Zi-Guo |
author_sort | Zhang, Xirui |
collection | PubMed |
description | Since the SARS-CoV-2 outbreak, pharmaceutical companies and researchers worldwide have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The potential pathogen responsible for Coronavirus Disease 2019 (COVID-19), SARS-CoV-2, belongs to a novel lineage of beta coronaviruses in the subgenus arbovirus. Antiviral drugs, convalescent plasma, monoclonal antibodies, and vaccines are effective treatments for SARS-CoV-2 and are beneficial in preventing infection. Numerous studies have already been conducted using the genome sequence of SARS-CoV-2 in comparison with that of other SARS-like viruses, and numerous treatments/prevention measures are currently undergoing or have already undergone clinical trials. We summarize these studies in depth in the hopes of highlighting some key details that will help us to better understand the viral origin, epidemiology, and treatments of the virus. |
format | Online Article Text |
id | pubmed-9780920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97809202022-12-24 SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments Zhang, Xirui Yuan, Hao Yang, Zipeng Hu, Xiaoyu Mahmmod, Yasser S. Zhu, Xiaojing Zhao, Cuiping Zhai, Jingbo Zhang, Xiu-Xiang Luo, Shengjun Wang, Xiao-Hu Xue, Mengzhou Zheng, Chunfu Yuan, Zi-Guo Vaccines (Basel) Review Since the SARS-CoV-2 outbreak, pharmaceutical companies and researchers worldwide have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The potential pathogen responsible for Coronavirus Disease 2019 (COVID-19), SARS-CoV-2, belongs to a novel lineage of beta coronaviruses in the subgenus arbovirus. Antiviral drugs, convalescent plasma, monoclonal antibodies, and vaccines are effective treatments for SARS-CoV-2 and are beneficial in preventing infection. Numerous studies have already been conducted using the genome sequence of SARS-CoV-2 in comparison with that of other SARS-like viruses, and numerous treatments/prevention measures are currently undergoing or have already undergone clinical trials. We summarize these studies in depth in the hopes of highlighting some key details that will help us to better understand the viral origin, epidemiology, and treatments of the virus. MDPI 2022-12-14 /pmc/articles/PMC9780920/ /pubmed/36560555 http://dx.doi.org/10.3390/vaccines10122145 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Zhang, Xirui Yuan, Hao Yang, Zipeng Hu, Xiaoyu Mahmmod, Yasser S. Zhu, Xiaojing Zhao, Cuiping Zhai, Jingbo Zhang, Xiu-Xiang Luo, Shengjun Wang, Xiao-Hu Xue, Mengzhou Zheng, Chunfu Yuan, Zi-Guo SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments |
title | SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments |
title_full | SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments |
title_fullStr | SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments |
title_full_unstemmed | SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments |
title_short | SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments |
title_sort | sars-cov-2: an updated review highlighting its evolution and treatments |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780920/ https://www.ncbi.nlm.nih.gov/pubmed/36560555 http://dx.doi.org/10.3390/vaccines10122145 |
work_keys_str_mv | AT zhangxirui sarscov2anupdatedreviewhighlightingitsevolutionandtreatments AT yuanhao sarscov2anupdatedreviewhighlightingitsevolutionandtreatments AT yangzipeng sarscov2anupdatedreviewhighlightingitsevolutionandtreatments AT huxiaoyu sarscov2anupdatedreviewhighlightingitsevolutionandtreatments AT mahmmodyassers sarscov2anupdatedreviewhighlightingitsevolutionandtreatments AT zhuxiaojing sarscov2anupdatedreviewhighlightingitsevolutionandtreatments AT zhaocuiping sarscov2anupdatedreviewhighlightingitsevolutionandtreatments AT zhaijingbo sarscov2anupdatedreviewhighlightingitsevolutionandtreatments AT zhangxiuxiang sarscov2anupdatedreviewhighlightingitsevolutionandtreatments AT luoshengjun sarscov2anupdatedreviewhighlightingitsevolutionandtreatments AT wangxiaohu sarscov2anupdatedreviewhighlightingitsevolutionandtreatments AT xuemengzhou sarscov2anupdatedreviewhighlightingitsevolutionandtreatments AT zhengchunfu sarscov2anupdatedreviewhighlightingitsevolutionandtreatments AT yuanziguo sarscov2anupdatedreviewhighlightingitsevolutionandtreatments |